Abstract: A unit in the form of a bubble pack for creating an anaerobic gaseous atmosphere in an upright container and for indicating the presence of the anaerobic atmosphere in the container. One bubble of the pack houses acid-containing ampoules while another bubble houses a tablet which generates hydrogen and carbon dioxide when activated by squeezing the first bubble to crush the ampoules and release the acid. Gas flows from the second bubble, through the first bubble and then into the container and enters still another bubble which houses an ampoule containing a redox color indicating liquid. When the latter ampoule is crushed, the liquid moistens an absorbent pad which changes colors as the atmosphere of the container changes from aerobic to anaerobic. The pack also carries catalyst pellets to promote a reaction between the generated hydrogen and the oxygen in the container.

Abstract: An aqueous solution of 5-aminosalicylic acid (5-ASA) and a nontoxic alkali, alkali metal or alkaline earth metal salt of 5-aminosalicylic acid having a pH of 3-5 is disclosed. The sole buffer in the solution is that intrinsically formed by 5-aminosalicylic acid and its alkali, alkali metal or alkaline earth metal salt. The solutions preferably also contain an antioxidant and a metal complexing agent. In preferrred practice, the 5-ASA salt is formed in situ by addition of an alkali, alkali metal or alkaline earth metal hydroxide to a solution of 5-ASA. The solution is stable and does not significantly discolor due to 5-ASA decomposition for extended periods of time.

Abstract: The titled ester, especially having the (2S,3S)-configuration, which is an intermediate for the production of diltiazem, is provided. Very high yields are obtainable.

Abstract: Compounds are disclosed having the formula: ##STR1## in which R.sub.1 is a C.sub.1 l to C.sub.12 alkyl, said alkyl being straight or branched chain, saturated or unsaturated, monosubstituted or unsubstituted, said substituents being selected from piperidine, pyrrolidine, morpholine, thiomorpholine or cycloalkyl of 3 to 7 carbons, a cycloalkyl of 3 to 9 carbons, a lower alkylcycloalkyl of 4 to 9 carbons, or a polycycloalkyl of 2 to 3 rings containing 7 to 12 carbons;R.sub.

Abstract: Certain 1,5-benzothiazepines are useful intermediates or pharamceuticals.

Abstract: 2-Aromatic-3-HALobenzothizepines are prepared by reaction of a 2,3-dihydro-2-aromatic-3-hydroxybenzothiazepine with a thionyl HALide. For example, dl-cis-2-(4-methoxyphenyl)-2,3-dihydro-3-hydroxy-1, 5-benzothiazzepin-4(5H)-one relfuxed with thionyl chloride can prepare E-2-(4-methoxyphenyl)-3-chloro-1,5-benzothiazepin-4(5H)-one in 66 percent yield.

Abstract: The four stereoisomers are disclosed having the formula: ##STR1## in which the asymmetric centers a and b are the same or different. The compounds are derived from the (+) and (-) alcohols and the (+) and (-) dihydropyridines and have either the absolute R or S configuration. Also disclosed are pharmaceutical compositions comprising an effective amount of the compounds in a pharmaceutically acceptable carrier and methods for producing cardiotonic activity using the compositions.

Abstract: An alpha-hydroxyl-alpha,alpha-di(inert-substituted)-gamma',delta'-yne ketone can be prepared by a procedure comprising contacting an acetylenic Grignard reagent with an alpha-hydroxyl-alpha,alpha-di(inert substituted)-alpha',beta'-ene ketone, and the alpha-hydroxyl-alpha,alpha-di(inert-substituted)-alpha',beta'-ene ketone can be prepared by a procedure comprising steps of contacting, first, an alkoxy allene with a lithium donating organic agent, second, product of the first step with a di(inert-substituted)ketone, and third, product of the second step with an acidic substance.

Abstract: Seizures are ameliorated with certain benzothiazepines.

Abstract: Bismuth salts of phosphorylated and/or sulfonated saccharides are prepared from a corresponding metal salt reactant, a water soluble organic acid, and a bismuth substance. For example, a complex salt of bismuth hydroxide sucrose octasulfate can be prepared in high yield and good purity from potassium sucrose octasulfate, trichloroacetic acid, trifluoracetic acid or 4-methylbenzenesulfonic acid, and bismuth hydroxide. Corresponding hydrogen phosphorylated and/or sulfonated saccharides may be intermediate products.

Abstract: Bismuth salts of phosphorylated and/or sulfonated saccharides can be prepared in one reaction vessel from a corresponding metal salt reactant, a water soluble organic acid, and a bismuth substance. For example, a complex salt of bismuth hydroxide sucrose octasulfate can be prepared in high yield and good purity from potassium sucrose octasulfate, trifluoracetic acid, and bismuth hydroxide.

Abstract: Bismuth (phosph/sulf)ated saccharides are useful in ameliorating gastrointestinal disorders associated with Campylobacter-like organisms such as, for example, Campylobacter pylori. For example, compositions containing a complex salt of bismuth hydroxide sucrose octasulfate can be thus employed to treat Type B gastritis.

Abstract: The titled compositions are useful as pharmaceuticals in ameliorating disorders associated with gastric mucosal damage. For example, compositions containing a complex salt of bismuth hydroxide sucrose octasulfate can be thus employed.

Abstract: The use of sulfated oligosaccharides, particularly mono- and disaccharides, and their salts to enhance healing of wounds is described. Preferred saccharides are those having three or more sulfate groups, with persulfation being most preferred. Preferred salts are the soluble salts most preferably the alkali metal salts, particularly potassium and sodium salts. Sucrose octosulfate is the most preferred material. The saccharides may be used in any form, including liquids, gels or time release polymers. In preferred practice the saccharide is used in combination with collagen. Wounds, in particular those ocurring in the skin and bone tissues, may be treated with the compositions. Wound healing is promoted even in wounds, such as decubitis ulcers, which are commonly resistent to the natural healing process.

Abstract: In general, the present invention provides, in one aspect, a process comprising contacting a 2-Aminothiophenol with an optically active 3-(4-alkyloxyphenyl)glycidic acid acyclic alkyl ester by step(s) under conditions such that an optically active 2-hydroxy-3-(4-alkyloxyphenyl)-3-(2-Aminophenylthio)propionic acid acyclic alkyl ester is prepared. Another aspect comprises the optically active 2-hydroxy-3-(4-alkyloxyphenyl)-3-(2-Aminophenylthio)propionic acid acyclic alkyl ester. A preferred aspect is a process comprising contacting 2-aminothiophenol per se with a 3-(4-methoxyphenyl)glycidic acid methyl ester by step(s) under conditions such that a 2-hydroxy-3-(4-methoxyphenyl)-3-(2-aminophenylthio)propionic acid methyl ester is prepared.

Abstract: Disclosed is a method for preparing poly(2-hydroxyethyl methacrylate) polymers (PHEMA) by a precipitation/suspension polymerization technique wherein a reaction mixture comprising hydroxyethyl methacrylate monomer (HEMA), solvent, and a free-radical initiator is subjected to heating for a time adequate for said PHEMA to be formed. The improvement in process of the present invention comprises restricting said HEMA to contain less than about 0.5 wt-% polyfunctional acrylate content, incorporating a suspending agent in said reaction mixture, agitating said reaction mixture during said heating, and restricting said solvent to one having a solubility parameter of between about 7.5 and 9, to produce PHEMA polymer particles ranging in size from about 30 to 1,000 microns and having a molecular weight ranging from about 500,000 to 2,000,000.

Abstract: Optically active 3-(4-methoxyphenyl)glycidic acid alkyl esters of high enantiomeric purity can be prepared through optical resolution of a racemic or optically enriched sample of a 3-(4-methoxyphenyl) glycidic acid. The alkali metal salt of the acid, generated in situ by hydrolysis of the corresponding alkyl ester with an alkali metal hydroxide is contacted with a suitable resolving agent such as an optically pure amine to form the corresponding diastereomeric salts. The desired diastereomeric salt is separated from the mixture and transformed to an alkali metal salt, which optionally without isolation is converted into the desired alkyl ester of high enantiomeric purity.

Abstract: A method for ameliorating or preventing generalized tonic-clonic type epileptic seizures in mammals is provided. The method involves systemically administering to a mammal in need of such treatment a compound having the formula ##STR1## wherein X is hydrogen, a lower straight chain or branched alkyl, hydroxy, a halogen or a lower straight chain or branched alkyl halide; Y is a lower straight chain or branched alkyl; R.sub.1 is hydrogen, hydroxy or acetyloxy; R.sub.2 and R.sub.3 are each a lower straight chain or branched alkyl or a non-aromatic cycloalkyl or together are a heterocyclic, and pharmaceutically acceptable salts thereof in an amount effective to ameliorate or prevent generalized tonic-clonic type seizures. Preferred compounds are those in which X is hydrogen or 8-chloro, Y is ethyl, R.sub.1 is acetyloxy and R.sub.2 and R.sub.3 are each methyl.

Abstract: Seizures are ameliorated with certain benzothiazepines.